UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (60) 60
female (55) 55
breast neoplasms - drug therapy (49) 49
life sciences & biomedicine (46) 46
science & technology (46) 46
breast cancer (39) 39
oncology (39) 39
breast neoplasms - pathology (32) 32
middle aged (23) 23
aged (20) 20
docetaxel (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
adult (18) 18
chemotherapy (18) 18
treatment outcome (17) 17
chemotherapy, adjuvant (15) 15
anastrozole (14) 14
cancer (14) 14
disease-free survival (14) 14
paclitaxel (14) 14
trastuzumab (13) 13
neoplasm metastasis (12) 12
randomized controlled trials as topic (11) 11
tamoxifen (11) 11
taxoids (10) 10
antineoplastic agents, phytogenic - therapeutic use (9) 9
doxorubicin - administration & dosage (9) 9
neoplasm staging (9) 9
paclitaxel - administration & dosage (9) 9
prognosis (9) 9
taxoids - therapeutic use (9) 9
antineoplastic agents - therapeutic use (8) 8
doxorubicin (8) 8
nitriles - therapeutic use (8) 8
paclitaxel - analogs & derivatives (8) 8
triazoles - therapeutic use (8) 8
abridged index medicus (7) 7
aged, 80 and over (7) 7
antibodies, monoclonal, humanized (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
care and treatment (7) 7
disease progression (7) 7
metastasis (7) 7
paclitaxel - therapeutic use (7) 7
pharmacology & pharmacy (7) 7
postmenopause (7) 7
adjuvant (6) 6
adjuvant treatment (6) 6
antibodies, monoclonal - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
aromatase inhibitor (6) 6
aromatase inhibitors (6) 6
breast neoplasms - metabolism (6) 6
cyclophosphamide - administration & dosage (6) 6
drug therapy (6) 6
health aspects (6) 6
medicine & public health (6) 6
postmenopausal (6) 6
quality of life (6) 6
research (6) 6
survival analysis (6) 6
taxoids - administration & dosage (6) 6
animals (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
breast neoplasms (5) 5
breast neoplasms - mortality (5) 5
cancer therapies (5) 5
dose-response relationship, drug (5) 5
exemestane (5) 5
letrozole (5) 5
tamoxifen - therapeutic use (5) 5
vinblastine - analogs & derivatives (5) 5
analysis (4) 4
androstadienes - adverse effects (4) 4
antineoplastic agents, hormonal - administration & dosage (4) 4
antineoplastic agents, hormonal - adverse effects (4) 4
antineoplastic agents, hormonal - pharmacology (4) 4
aromatase inhibitors - therapeutic use (4) 4
breast neoplasms - chemistry (4) 4
breast neoplasms - diagnosis (4) 4
breast neoplasms - genetics (4) 4
breast neoplasms - therapy (4) 4
capecitabine (4) 4
clinical trials (4) 4
clinical trials, phase iii as topic (4) 4
combined modality therapy (4) 4
cyclophosphamide (4) 4
drug therapy, combination (4) 4
epirubicin (4) 4
hematology, oncology and palliative medicine (4) 4
life sciences (4) 4
male (4) 4
metastatic (4) 4
metastatic breast cancer (4) 4
nitriles - adverse effects (4) 4
receptor, erbb-2 - analysis (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Therapeutics and clinical risk management, ISSN 1176-6336, 2008, Volume 4, Issue 1, pp. 189 - 204
... of aromatase inhibitors in the treatment of breast cancer Jean-Marc A Nabholtz Breast Cancer Research Institute La Prandie, Valojoulx, France Correspondence: Prof Jean... 
Adjuvant | Breast cancer | Aromatase inhibitors | Safety profile | Evidence-based medicine | breast cancer | aromatase inhibitors | adjuvant | safety profile | Review
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents | Index Medicus | Life Sciences
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 28, pp. 19463 - 19468
BackgroundSince the approval of the first poly (adenosine diphosphate [ADP]) ribose polymerase inhibitor (PARPi; olaparib [Lynparza™]) for platinum-sensitive... 
OvCa | Molecular diagnostics | NGS | TBRCA1/2
Journal Article
2000, ISBN 9780864710727, 133
Book